Developing small molecules targeting KIAA1199 or KIAA1199 specific neutralizing monoclonal antibodies will be useful in examining their therapeutic effects in bone diseases, such as non-healed bone fractures or osteoporosis. Here, CEMIP is linked to osteoporosis.